REDONDO BEACH, Calif., Nov. 17 /PRNewswire/ -- In a move that opens the door for computed radiography to be more widely available to healthcare providers nationwide, the U.S. Food and Drug Administration (FDA) today announced that it has granted clearance to Radlink, Inc. to proceed with the sale and distribution of its breakthrough CR Pro machine.
Radlink, a fast-growing provider of affordable medical imaging systems to healthcare providers, has been attracting attention in the U.S. medical imaging business for its computed radiography system that has been in development for two years. The system, CR Pro, utilizes Radlink’s sealed fiber-optic laser technology (patent pending) to deliver high-resolution, diagnostic-quality images that provide long-term image quality.
“The true breakthrough of CR Pro is that it is built on a platform that allows it to be sold at a substantially lower cost than all of its competitors, finally making computed radiography systems available to healthcare providers who have previously been unable to afford the technology,” said Thomas Hacking, chief executive officer of Radlink. “We believe that our proprietary laser technology will not only compete favorably in the U.S. on price, but we also believe it’s superior to the existing standard because it provides enhanced resolution to the scanned image and as a result x-rays can be viewed more clearly.”
Radlink is a Redondo Beach, Calif.-based global radiography company that provides a wide range of medical film-to-digital image conversion, storage and delivery services to healthcare providers. The company markets its products and services to customers involved in medical film diagnostics worldwide, including radiology groups, physicians, diagnostic imaging centers, hospitals and health clinics. For more information, please go to www.eradlink.com.
Radlink, Inc.
CONTACT: Amy Goldsmith, +1-310-440-0646, or Daryn Teague, +1-661-297-5292,both of GK Communications, for Radlink
Web site: http://www.eradlink.com/
